X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7238) 7238
Magazine Article (87) 87
Book Chapter (31) 31
Book / eBook (8) 8
Dissertation (8) 8
Newsletter (6) 6
Newspaper Article (6) 6
Publication (5) 5
Conference Proceeding (2) 2
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5464) 5464
female (2690) 2690
warfarin (2675) 2675
anticoagulants (2602) 2602
male (2572) 2572
administration, oral (2549) 2549
anticoagulants - administration & dosage (2158) 2158
aged (2136) 2136
anticoagulants - therapeutic use (2112) 2112
middle aged (1883) 1883
hematology (1625) 1625
anticoagulants - adverse effects (1618) 1618
atrial fibrillation (1603) 1603
risk factors (1541) 1541
peripheral vascular disease (1389) 1389
thromboembolism (1308) 1308
stroke (1293) 1293
adult (1209) 1209
oral anticoagulant-therapy (1177) 1177
cardiac & cardiovascular systems (1126) 1126
treatment outcome (1071) 1071
prevention (1070) 1070
aged, 80 and over (1068) 1068
venous thromboembolism (1023) 1023
management (1009) 1009
oral anticoagulants (989) 989
international normalized ratio (977) 977
atrial fibrillation - drug therapy (965) 965
hemorrhage - chemically induced (964) 964
risk (940) 940
dabigatran (880) 880
atrial-fibrillation (871) 871
therapy (862) 862
medicine, general & internal (858) 858
oral anticoagulation (839) 839
thrombosis (836) 836
rivaroxaban (817) 817
warfarin - therapeutic use (771) 771
pharmacology & pharmacy (770) 770
stroke - prevention & control (736) 736
medicine & public health (724) 724
anticoagulation (720) 720
warfarin - administration & dosage (707) 707
care and treatment (686) 686
atrial fibrillation - complications (678) 678
bleeding (645) 645
warfarin - adverse effects (645) 645
antithrombotic therapy (640) 640
patients (637) 637
retrospective studies (628) 628
deep-vein thrombosis (604) 604
cardiac arrhythmia (587) 587
surgery (587) 587
drug therapy (577) 577
analysis (573) 573
molecular-weight heparin (572) 572
time factors (565) 565
risk assessment (556) 556
hemorrhage (551) 551
cardiology (548) 548
stroke prevention (535) 535
thromboembolism - prevention & control (533) 533
aspirin (520) 520
vitamin k - antagonists & inhibitors (518) 518
apixaban (498) 498
prospective studies (497) 497
mortality (466) 466
abridged index medicus (452) 452
risk-factors (451) 451
safety (445) 445
health aspects (423) 423
follow-up studies (412) 412
recurrence (411) 411
internal medicine (410) 410
dosage and administration (408) 408
stroke - etiology (407) 407
blood coagulation - drug effects (403) 403
prothrombin time (399) 399
direct oral anticoagulants (398) 398
pulmonary-embolism (382) 382
clinical trials (375) 375
thrombin (368) 368
research (365) 365
venous thrombosis (354) 354
adolescent (353) 353
fibrillation (342) 342
metaanalysis (340) 340
pulmonary embolism (334) 334
anticoagulants - pharmacology (333) 333
bleeding complications (327) 327
medical research (326) 326
dose-response relationship, drug (323) 323
complications (317) 317
vitamin k (312) 312
venous thrombosis - drug therapy (311) 311
venous thromboembolism - drug therapy (310) 310
cardiovascular diseases (309) 309
heparin (308) 308
oral anticoagulant (301) 301
drug administration schedule (298) 298
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6960) 6960
German (132) 132
French (120) 120
Spanish (79) 79
Italian (62) 62
Russian (54) 54
Japanese (47) 47
Portuguese (36) 36
Hungarian (15) 15
Polish (15) 15
Czech (8) 8
Danish (8) 8
Turkish (7) 7
Norwegian (6) 6
Dutch (5) 5
Serbian (5) 5
Chinese (4) 4
Korean (4) 4
Romanian (4) 4
Swedish (4) 4
Hebrew (3) 3
Croatian (2) 2
Bulgarian (1) 1
Georgian (1) 1
Icelandic (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant... 
GAMMA-CARBOXYGLUTAMIC ACID | INTRAVENOUS PHYTONADIONE VITAMIN-K-1 | FACTOR-XA INHIBITOR | VENOUS LIMB GANGRENE | EUROPEAN CONCERTED ACTION | LOW-INTENSITY WARFARIN | RESPIRATORY SYSTEM | VITAMIN-K ANTAGONISTS | TOTAL HIP-REPLACEMENT | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This... 
COMPUTERIZED DECISION-SUPPORT | INTENSITY WARFARIN THERAPY | DEFINITE ANTIPHOSPHOLIPID SYNDROME | RESPIRATORY SYSTEM | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | DEEP-VEIN THROMBOSIS | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | ACUTE VENOUS THROMBOEMBOLISM | ORAL VITAMIN-K | CRITICAL CARE MEDICINE | United States | Humans | Decision Support Systems, Clinical | Heparin - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Heparin - adverse effects | Heparin - pharmacokinetics | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Drug Interactions | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Thrombosis - prevention & control | Patient Education as Topic | Polysaccharides - therapeutic use | Drug Administration Schedule | Administration, Oral | Hemorrhage - therapy | Polysaccharides - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | International Normalized Ratio | Thrombosis - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Self Care | Polysaccharides - pharmacokinetics | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9872, pp. 1107 - 1115
Journal Article
Journal Article
Current pharmaceutical design, ISSN 1381-6128, 01/2010, Volume 16, Issue 2, pp. 187 - 203
Journal Article
Journal Article
PLoS medicine, ISSN 1549-1676, 2018, Volume 15, Issue 3, p. e1002528
.... Despite good evidence for the reduction of stroke risk with anticoagulant therapy, there remains significant undertreatment... 
GLOBAL BURDEN | PHYSICIAN ORDER ENTRY | MEDICINE, GENERAL & INTERNAL | HOSPITALIZED-PATIENTS | PREVENT VENOUS THROMBOEMBOLISM | METAANALYSIS | SAFETY | ORAL ANTICOAGULANTS | ELECTRONIC ALERTS | SYSTEMS | ANTITHROMBOTIC TREATMENT | Primary Health Care - methods | Stroke - prevention & control | Quality Improvement - organization & administration | Anticoagulants - administration & dosage | Guideline Adherence - standards | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Atrial Fibrillation - complications | Decision Support Systems, Clinical | Male | Anticoagulants - adverse effects | Risk Adjustment - methods | Stroke - etiology | Sweden | Female | Aged | Electronic Health Records - standards | Practice Guidelines as Topic | Decision support systems | Usage | Atrial fibrillation | Anticoagulants (Medicine) | Management | Patient compliance | Risk factors | Stroke (Disease) | Prevention | Complications and side effects | Dosage and administration | Drug therapy | Health aspects | Health care | Therapy | Transient ischemic attack | Physicians | Catchments | Risk | Electronic medical records | Bleeding | Guidelines | Incidence | Fibrillation | Ischemia | Clusters | Thromboembolism | Medical personnel | Anticoagulants | Stroke | Automation | Health risks | Regression analysis | Patients | Adhesion | Morbidity | Catchment areas | Reproducibility | Randomization
Journal Article